Abstract
Dengue is one of the most important arboviral infections worldwide, infecting up to 390 million people and causing 25,000 deaths annually. Although a licensed dengue vaccine is available, it is not efficacious against dengue serotypes that infect people living in South East Asia, where dengue is an endemic disease. Hence, there is an urgent need to develop an efficient dengue vaccine for this region. Data from different clinical trials indicate that a successful dengue vaccine must elicit both neutralizing antibodies and cell mediated immunity. This can be achieved by designing a multi-epitope peptide vaccine comprising B, CD8+ and CD4+ T cell epitopes. As recognition of T cell epitopes are restricted by human leukocyte antigens (HLA), T cell epitopes which are able to recognize several major HLAs will be preferentially included in the vaccine design. While peptide vaccines are safe, biocompatible and cost-effective, it is poorly immunogenic. Strategies to improve its immunogenicity by the use of long peptides, adjuvants and nanoparticle delivery mechanisms are discussed.
Keywords: Dengue, peptide vaccine, multi-epitope, synthetic peptides, HLA, cell mediated immunity.
Current Pharmaceutical Design
Title:Development of Peptide Vaccines in Dengue
Volume: 24 Issue: 11
Author(s): Kavita Reginald, Yanqi Chan, Magdalena Plebanski and Chit Laa Poh*
Affiliation:
- Research Centre for Biomedical Sciences, Sunway University, Bandar Sunway, Subang Jaya, Selangor,Malaysia
Keywords: Dengue, peptide vaccine, multi-epitope, synthetic peptides, HLA, cell mediated immunity.
Abstract: Dengue is one of the most important arboviral infections worldwide, infecting up to 390 million people and causing 25,000 deaths annually. Although a licensed dengue vaccine is available, it is not efficacious against dengue serotypes that infect people living in South East Asia, where dengue is an endemic disease. Hence, there is an urgent need to develop an efficient dengue vaccine for this region. Data from different clinical trials indicate that a successful dengue vaccine must elicit both neutralizing antibodies and cell mediated immunity. This can be achieved by designing a multi-epitope peptide vaccine comprising B, CD8+ and CD4+ T cell epitopes. As recognition of T cell epitopes are restricted by human leukocyte antigens (HLA), T cell epitopes which are able to recognize several major HLAs will be preferentially included in the vaccine design. While peptide vaccines are safe, biocompatible and cost-effective, it is poorly immunogenic. Strategies to improve its immunogenicity by the use of long peptides, adjuvants and nanoparticle delivery mechanisms are discussed.
Export Options
About this article
Cite this article as:
Reginald Kavita , Chan Yanqi , Plebanski Magdalena and Poh Laa Chit *, Development of Peptide Vaccines in Dengue, Current Pharmaceutical Design 2018; 24(11) . https://dx.doi.org/10.2174/1381612823666170913163904
DOI https://dx.doi.org/10.2174/1381612823666170913163904 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Virological and Clinical Response to Interferon-Free Regimens in Patients with HCV-Related Mixed Cryoglobulinemia: Preliminary Results of a Prospective Pilot Study
Current Drug Targets Ovarian Cancer Biomarkers: Headway Towards Early Diagnosis
Current Chemical Biology Can Systems Biology Understand Pathway Activation? Gene Expression Signatures as Surrogate Markers for Understanding the Complexity of Pathway Activation
Current Genomics A Review of Sirt1 and Sirt1 Modulators in Cardiovascular and Metabolic Diseases
Recent Patents on Cardiovascular Drug Discovery Immune System Modulates the Function of Adult Neural Stem Cells
Current Immunology Reviews (Discontinued) Androstenediol Modulates Sepsis Induced Alterations of Survival and Immune Functions in a Murin Model of Sepsis
Medicinal Chemistry GPR55, a Lysophosphatidylinositol Receptor with Cannabinoid Sensitivity?
Current Topics in Medicinal Chemistry Stimulation of DDX3 Expression by Ginsenoside Rg3 through the Akt/p53 Pathway Activates the Innate Immune Response via TBK1/IKKε/IRF3 Signalling
Current Medicinal Chemistry Intestinal Epithelial Barrier Dysfunction in Disease and Possible Therapeutical Interventions
Current Medicinal Chemistry The Effects of Different Antioxidants on the Activity of Cerebrocortical MnSOD and Na,K-ATPase from post mortem Alzheimer’s Disease and Age-matched Normal Brains
Current Alzheimer Research Osteocyte biology and space flight
Current Biotechnology Anti-Inflammatory Effect of Crocus sativus on Serum Cytokine Levels in Subjects with Metabolic Syndrome: A Randomized, Double-Blind, Placebo- Controlled Trial
Current Clinical Pharmacology Poly(ADP-Ribose)Polymerase 1 (PARP-1) Activation and Ca<sup>2+</sup> Permeable α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid (AMPA) Channels in Post-Ischemic Brain Damage: New Therapeutic Opportunities?
CNS & Neurological Disorders - Drug Targets BRCA-FA Pathway as a Target for Anti-Tumor Drugs
Anti-Cancer Agents in Medicinal Chemistry Therapies of Hematological Malignancies: An Overview of the Potential Targets and Their Inhibitors
Current Chemical Biology The Clinical Application of Infrared Thermal Imaging in Lumbocrural Pain
Current Medical Imaging Molecular and Cellular Mechanisms of Hexavalent Chromium-Induced Lung Cancer: An Updated Perspective
Current Drug Metabolism Obesity and Metabolic Syndrome Affect the Cholinergic Transmission a nd Cognitive Functions
CNS & Neurological Disorders - Drug Targets Extending the Clinical Horizons of Mucosal Bacterial Vaccines: Current Evidence and Future Prospects
Current Drug Targets A Role for the Adenosine ADORA2B Receptor in Midazolam Induced Cognitive Dysfunction
Current Pharmaceutical Design